Research programme: TRPV cation channel inhibitors - Purdue Pharma
Alternative Names: BCTC; Research programme: vanilloid receptor 1 antagonists - Purdue PharmaLatest Information Update: 21 Jul 2010
At a glance
- Originator Purdue Pharma
- Class Piperazines
- Mechanism of Action TRPV cation channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 21 Jul 2010 Discontinued - Preclinical for Pain in USA (unspecified route)
- 23 Sep 2003 Preclinical trials in Pain in USA (unspecified route)